☆ 4.7 Article

Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

Teresa Brevini et al.

Summary: Modulating the expression of angiotensin-converting enzyme 2 (ACE2) through farnesoid X receptor (FXR) can reduce susceptibility to SARS-CoV-2 infection, as shown in various tissues and organoids in vitro, in vivo, and ex vivo. The use of z-guggulsterone and ursodeoxycholic acid (UDCA) can downregulate ACE2 and decrease viral infection, including in the nasal epithelium. Clinical data also indicate positive outcomes with UDCA treatment in SARS-CoV-2 infection. These findings suggest that targeting the FXR-ACE2 pathway could be a potential strategy for preventing COVID-19.

NATURE (2023)

Add to Collection

Article Multidisciplinary Sciences

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir

Sho Iketani et al.

Summary: Nirmatrelvir, an experimental oral antiviral, has shown clinical usefulness against COVID-19. However, there is concern that SARS-CoV-2 could develop resistance to this drug. In vitro studies have demonstrated that highly resistant viruses can emerge from SARS-CoV-2 when exposed to Nirmatrelvir, with mutations in the 3CL protease. These findings provide insights into the mechanisms of resistance and can inform the development of next-generation protease inhibitors.

NATURE (2023)

Add to Collection

Article Chemistry, Multidisciplinary

Development of Highly Potent Noncovalent Inhibitors of SARS- CoV-2 3CLpro

Ningke Hou et al.

Summary: A specific noncovalent inhibitor called WU-04 has been developed, which effectively blocks the replication of SARS-CoV-2 and other coronaviruses. It shows high potency as a pan-inhibitor of coronavirus 3CLpro and has similar activity to the drug Nirmatrelvir in treating SARS-CoV-2.

ACS CENTRAL SCIENCE (2023)

Add to Collection

Review Chemistry, Multidisciplinary

4′-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives

Junbiao Chang

Summary: Modified nucleosides have therapeutic potential in antiviral treatments, but face new challenges in the era of the COVID-19 pandemic. 4'-Modified nucleosides are an important subclass that can enhance antiviral activity and safety. Several 4'-modified nucleoside drug candidates have progressed into clinical stages, with FNC showing promise in treating HIV-1 and COVID-19.

ACCOUNTS OF CHEMICAL RESEARCH (2022)

Add to Collection

Article Pharmacology & Pharmacy

Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis

Daniele Focosi et al.

Summary: Despite massive usage, the global level of remdesivir resistance is very low during the COVID-19 pandemic.

ANTIVIRAL RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2

Pengcheng Han et al.

Summary: The study found that the omicron variant, unlike other variants, has a similar affinity to the human receptor ACE2 as the prototype variant. Multiple mutations in the omicron variant may compensate for both immune escape and transmissibility. The complex structures of the omicron and delta variants binding to ACE2 provide insights into how specific mutations affect the binding.

CELL (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron

Zhen Cui et al.

Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly worldwide due to its increased fitness, with spike structures that maintain stability for receptor recognition but compromise viral fusion efficiency. By altering amino acids and structures, it evades recognition by most antibodies, facilitating immune escape. The research sheds light on conserved regions for the development of broad-spectrum vaccines.

CELL (2022)

Add to Collection

Article Cell Biology

Comparison of viral RNA-host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2

Shaojun Zhang et al.

Summary: Comparative analysis revealed common and virus-specific host responses, identifying vRNA-associated proteins that either promote or restrict viral infection. The study highlighted how SARS-CoV-2 hijacks the host factor IGF2BP1 to stabilize vRNA and enhance viral translation. Interactome-informed drug repurposing led to the identification of potential broad-spectrum antivirals, including Cepharanthine and Trifluoperazine, with efficacy against the emerging SARS-CoV-2 B.1.351 variant.

CELL RESEARCH (2022)

Add to Collection

Letter Virology

In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery

Zhonglei Wang et al.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Article Chemistry, Medicinal

Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L

Anneliese S. Ashhurst et al.

Summary: The study identifies cathepsin L as a key protease used by coronaviruses for cell entry and a potential drug target for antiviral treatment against SARS-CoV-2. The researchers discovered that gallinamide A and synthetic analogues are potent inhibitors of cathepsin L, showing promising antiviral activity against SARS-CoV-2. The combination with a TMPRSS2 inhibitor further enhances the antiviral effect.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses

Andreas Luttens et al.

Summary: Developing drug inhibitors targeting SARS-CoV-2 is crucial for saving lives and preparing for future outbreaks. Two virtual screening strategies were explored, resulting in the identification of compounds with inhibitory effects, including one compound with promising antiviral activity.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2022)

Add to Collection

Article Multidisciplinary Sciences

Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants

Kang Wang et al.

Summary: The Omicron variant of SARS-CoV-2 is highly resistant to neutralizing antibodies, which raises concerns about the effectiveness of antibody therapies and vaccines. A study found that individuals who received two or three doses of an inactivated SARS-CoV-2 vaccine had varying rates of seroconversion for neutralizing antibodies. The effectiveness of neutralizing antibodies against Omicron was significantly lower in individuals who received three vaccine doses. However, monoclonal antibodies derived from individuals who received three vaccine doses showed strong neutralizing activity against all variants of concern, including Omicron.

NATURE (2022)

Add to Collection

Review Cell Biology

Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design

Brandon Malone et al.

Summary: The molecular basis and complexity of coronavirus RNA-synthesizing machinery is still not fully understood. Recent research has focused on deciphering and understanding the structures, functions, and interactions of the subunits involved in SARS-CoV-2 replication and transcription. Both viral and host factors play a crucial role in coordinating RNA translation, replication, and transcription, making them potential targets for antiviral therapy.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2022)

Add to Collection

Review Cell Biology

Mechanisms of SARS-CoV-2 entry into cells

Cody B. Jackson et al.

Summary: The entry of SARS-CoV-2 into host cells is facilitated by the interaction between the viral spike protein and ACE2, leading to virus-cell membrane fusion, which has been extensively studied at the structural and cellular levels worldwide. This understanding has paved the way for the development of effective vaccines in response to the COVID-19 pandemic, caused by the infection with SARS-CoV-2.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

R. L. Gottlieb et al.

Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Chemistry, Medicinal

Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models

Yingjun Li et al.

Summary: The article reports that the parent nucleoside of remdesivir, GS-441524, shows potent inhibition of SARS-CoV-2 replication and has high efficacy in reducing viral titers in infected organs without notable toxicity in animal studies.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Multidisciplinary Sciences

Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody

Wanchao Yin et al.

Summary: The structures of the Omicron spike trimer and its interactions with ACE2 and an anti-Omicron antibody are reported. Most mutations in Omicron are located on the spike protein surface, altering binding to many existing antibodies. Compensating mutations in the ACE2-binding site enhance binding to ACE2. The therapeutic antibody JMB2002 maintains neutralizing activity against Omicron and inhibits ACE2 binding.

SCIENCE (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Computationally driven discovery of SARS-CoV-2 Mpro inhibitors: from design to experimental validation

Lea El Khoury et al.

Summary: We report a computationally driven discovery of new SARS-CoV-2 main protease (M-pro) inhibitors, whose potency has been significantly improved from initial non-covalent ligands to final covalent compound. The study highlights the power of structure-based computational strategies for drug design and provides insights for further optimization of M-pro inhibitors.

CHEMICAL SCIENCE (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay

Wenyue Cao et al.

Summary: The researchers developed an effective method to analyze the cellular potency of main protease (MPro) inhibitors for their toxicity and antiviral effect against SARS-CoV-2. Some antiviral agents showed weak cellular MPro inhibition potency, suggesting their involvement in interfering with other key steps in the virus life cycle. One of the inhibitors, MPI8, exhibited the highest cellular and antiviral potency, indicating the need for further research.

ACS CENTRAL SCIENCE (2022)

Add to Collection

Article Multidisciplinary Sciences

Toward wide-spectrum antivirals against coronaviruses: Molecular characterization of SARS-CoV-2 NSP13 helicase inhibitors

Gustavo R. Perez-Lemus et al.

Summary: This study investigates the structural coordination and dynamics of the SARS-CoV-2 Nsp13 helicase and its complexes with natural ligands using atomistic molecular dynamics simulations. The results reveal a complex communication network and activation mechanism among the five domains of Nsp13, which are modulated by the presence of ligands. The study also presents the binding free energy and mechanism of action for three small molecules that efficiently inhibit the previous SARS-CoV Nsp13 enzyme. These findings provide important insights for the rational design of broad-spectrum antivirals against coronaviruses.

SCIENCE ADVANCES (2022)

Add to Collection

Article Chemistry, Medicinal

Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2

Wenhao Dai et al.

Summary: A series of peptidomimetic aldehydes were designed and synthesized to target 3C(pro) of EV71 and SARS-CoV-2. Compound 18p showed potent antiviral and enzyme inhibitory activity, as well as good pharmacokinetic properties.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Chemistry, Medicinal

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

Naoya Kitamura et al.

Summary: This study discovered 23R, one of the most potent and selective noncovalent SARS-CoV-2 MPpro inhibitors reported to date, and a novel binding pocket in MPpro that can be explored for inhibitor design.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects

Hong-jie Qian et al.

Summary: VV116, an oral drug candidate against SARS-CoV-2, showed satisfactory safety and tolerability in healthy subjects, with no significant impact from food intake. These findings support further investigation of VV116 in patients with COVID-19.

ACTA PHARMACOLOGICA SINICA (2022)

Add to Collection

Article Pharmacology & Pharmacy

Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis

Martin Sachse et al.

Summary: The need for broad-spectrum, efficient antiviral treatments to combat emerging and re-emerging viruses has been highlighted by the COVID-19 pandemic. This study demonstrates that Plitidepsin, an antitumor agent, can effectively inhibit SARS-CoV-2 infection by disrupting the replication and morphogenesis of the virus.

ANTIVIRAL RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody

Cheng Li et al.

Summary: This study identifies two highly conserved regions on the Omicron variant receptor-binding domain that are recognized by broadly neutralizing antibodies, and generates a bispecific antibody that can simultaneously bind these regions, showing excellent therapeutic efficacy and neutralization breadth.

CELL (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Binding mode characterization of 13b in the monomeric and dimeric states of SARS-CoV-2 main protease using molecular dynamics simulations

Anita Kumari et al.

Summary: The study compared monomer and dimer forms of the main protease M-pro, revealing differences in the mechanism of binding between the potential COVID-19 inhibitor `13b' and the enzyme. Molecular dynamics simulations suggest that the presence of `13b' enhances the stability of M-pro, and protein structure analysis highlights key hot-spots in protein-ligand and protein-protein interactions.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2022)

Add to Collection

Article Chemistry, Medicinal

Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability

Bing Bai et al.

Summary: This study describes novel antiviral compounds against coronaviruses, which have good activity and stability, and show effective inhibition of SARS-CoV-2 replication. They also exhibit better selectivity index and broad-spectrum antiviral activity against different types of coronaviruses.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Infectious Diseases

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader et al.

Summary: A study conducted in COVID-19 patients admitted to hospital and requiring oxygen support found that remdesivir did not show significant clinical benefits compared to standard care alone.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Chemistry, Medicinal

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CLProtease Inhibitor Clinical Candidate for Treating COVID-19

Yuto Unoh et al.

Summary: S-217622 is the first oral noncovalent, nonpeptidic SARS-CoV-2 3CL protease inhibitor clinical candidate, which could be a potential oral agent for treating COVID-19.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Infectious Diseases

Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach

Rafael Dal-Re et al.

Summary: The first two oral antivirals, molnupiravir and nirmatrelvir-ritonavir, are now available in many countries for the treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised patients. They should be prescribed within 5 days of symptom onset and after confirming the SARS-CoV-2 infection. However, their availability will be limited due to manufacturing constraints.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Multidisciplinary Sciences

Molecular basis of receptor binding and antibody neutralization of Omicron

Qin Hong et al.

Summary: This study used cryo-electron microscopy to reveal the structural features of the Omicron variant spike protein and its interactions with the ACE2 receptor and antibodies, providing important insights for further research and design of vaccines targeting this variant.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529

Tongqing Zhou et al.

Summary: In this study, the cryo-electron microscopy structures of the B.1.1.529 (Omicron) variant of SARS-CoV-2 were determined, and receptor binding domain (RBD) antibodies were evaluated for their ability to bind and neutralize this variant. The study found that certain monoclonal antibodies still retained substantial inhibitory activity and identified combinations of antibodies with synergistic neutralization.

SCIENCE (2022)

Add to Collection

Article Multidisciplinary Sciences

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report

Shiv Gandhi et al.

Summary: This article reports a case of remdesivir resistance mutation in an immunocompromised patient with SARS-CoV-2 infection. The patient developed viral shedding recurrence and whole genome sequencing identified a mutation, E802D, in the nsp12 RNA-dependent RNA polymerase. In vitro experiments showed that this mutation increased remdesivir resistance but had a fitness cost in the absence of remdesivir. The patient achieved sustained clinical and virologic response with casirivimab-imdevimab treatment.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Clinical Neurology

Paxlovid™ Information From US Food & Drug Administration (FDA) and Guidance for AES Members

Jon A. Cokley et al.

Summary: This official statement provides information and guidance on the use of Paxlovid in patients taking antiseizure medications (ASMs). Concomitant use of Paxlovid with certain ASMs is contraindicated, as it may lead to loss of virologic response and development of resistance. Patients receiving ASMs metabolized by CYP3A4 may require closer monitoring while being treated with Paxlovid.

EPILEPSY CURRENTS (2022)

Add to Collection

Article Immunology

An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants

Yinzhong Shen et al.

Summary: VV116 is a safe and effective oral antiviral drug that shows better performance in the early onset of omicron infection.

EMERGING MICROBES & INFECTIONS (2022)

Add to Collection

News Item Critical Care Medicine

The future of Paxlovid for COVID-19

Talha Burki

LANCET RESPIRATORY MEDICINE (2022)

Add to Collection

Article Microbiology

An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron

Bao-Xue Quan et al.

Summary: This study reports a promising lead compound, Y180, for oral drug development against SARS-CoV-2. Y180, an inhibitor of the main protease (Mpro), demonstrated therapeutic efficacy against wild-type SARS-CoV-2 and its variants, including the Omicron variant, after oral administration. It improved survival in a humanized mouse model.

NATURE MICROBIOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19

Henrik Berg Rasmussen et al.

Summary: GS-441524 has the potential for oral treatment of Covid-19 and appears to be well-tolerated. The study suggests that lower doses of GS-441524 may be effective against Covid-19 and there are interspecies differences in oral uptake.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2022)

Add to Collection

Article Chemistry, Medicinal

Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2

Wenying Yu et al.

Summary: In this study, a novel inhibitor was developed with potent inhibitory effects against both PLpro and Mpro of SARS-CoV-2. The inhibitor can covalently inactivate the viral proteases and exhibits high specificity. Animal studies have shown that the inhibitor has significant antiviral activity.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1

Linjie Li et al.

Summary: The study reveals the differences in binding affinities between the four early sub-variants of the Omicron variant and human ACE2 receptor, providing insights into the structural basis for these differences.

CELL (2022)

Add to Collection

Article Microbiology

Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites

Sho Iketani et al.

Summary: This study systematically investigates the mutations of SARS-CoV-2 3CL protease using a yeast-based mutational scanning approach, and validates some of the results in authentic viruses. The research reveals the high malleability of 3CL protease, while identifying immutable residues that may serve as targets for future drug inhibitors.

CELL HOST & MICROBE (2022)

Add to Collection

Article Multidisciplinary Sciences

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system

Yuyong Zhou et al.

Summary: The oral protease inhibitor nirmatrelvir is crucial for preventing severe COVID-19, but the virus can develop resistance to it. This study identified multiple mutations that confer high resistance to nirmatrelvir, some of which decrease viral replication and protease activity, but still maintain high fitness. Other naturally occurring mutations can compensate for the fitness cost and promote viral escape. Molecular dynamics simulations showed that these mutations weaken the binding between nirmatrelvir and the protease. Additionally, the polymerase inhibitor remdesivir and monoclonal antibody bebtelovimab remained effective against nirmatrelvir-resistant variants, and combining them with nirmatrelvir enhanced treatment efficacy.

SCIENCE ADVANCES (2022)

Add to Collection

Article Multidisciplinary Sciences

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Yunlong Cao et al.

Summary: Omicron sublineages BA.2.12.1, BA.4 and BA.5 have higher transmissibility and increased evasion of neutralizing antibodies compared to the BA.2 lineage. They exhibit similar binding affinities to the ACE2 receptor as BA.2. BA.1 infection after vaccination boosts humoral immune memory against wild-type SARS-CoV-2, but these antibodies are largely evaded by BA.2 and BA.4/BA.5 variants.

NATURE (2022)

Add to Collection

Article Pharmacology & Pharmacy

In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2

Weijuan Shang et al.

Summary: FB2001 is a promising therapeutic agent in COVID-19 treatment that exhibits potent antiviral activity against various SARS-CoV-2 variants and shows improvement in pathological symptoms in the lungs and brains. It can be combined with remdesivir for better clinical outcomes. This drug candidate has been approved for Phase II/III clinical trial due to its good safety and tolerability.

ANTIVIRAL RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analog inhibitors

Liming Yan et al.

Summary: This study reveals the mechanism of SARS-CoV-2 RNA capping and provides atomic resolution structural details. It shows that the NiRAN domain plays a crucial role in RNAylation and the formation of GpppA. Moreover, triphosphorylated nucleotide analog inhibitors can inhibit RNAylation and GpppA formation by binding to nsp9. The conformational shift of the S-loop in NiRAN observed in the presence of sofosbuvir monophosphate suggests a possible mechanism for designing inhibitors.

CELL (2022)

Add to Collection

Article Medicine, General & Internal

Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study

Carlos K H Wong et al.

LANCET (2022)

Add to Collection

Article Medicine, General & Internal

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge

Ronen Arbel et al.

Summary: The study showed that among patients aged 65 years or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir compared to those who did not. However, no evidence of benefit was found in younger adults.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

Anupriya Aggarwal et al.

Summary: The study reveals that all Omicron variants significantly evade neutralizing antibodies from a range of vaccination and/or convalescent responses. The potency of therapeutic monoclonal antibodies is also reduced and varies across Omicron lineages. The key difference of the BA.5 variant from other Omicron sub-variants is the reversion to using the well-known ACE2-TMPRSS2 pathway, which was efficiently utilized by pre-Omicron lineages. Monitoring the impact of these changes on transmission and disease severity is crucial for ongoing tracking and management of Omicron waves globally.

EBIOMEDICINE (2022)

Add to Collection

Review Chemistry, Multidisciplinary

SARS-CoV-2 Main Protease Drug Design, Assay Development, and Resistance Studies

Bin Tan et al.

Summary: This article describes the development of antiviral drugs against SARS-CoV-2, including noncovalent and covalent main protease inhibitors, as well as the identification of drug-resistant mutants. It also introduces a cell-based assay for evaluating the cellular target engagement of inhibitors and provides guidance for the development of orally bioavailable Mpro inhibitors.

ACCOUNTS OF CHEMICAL RESEARCH (2022)

Add to Collection

Article Pharmacology & Pharmacy

Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment

Irine Pauly et al.

Summary: This study used a drug repurposing strategy to identify potential RdRp inhibitors for COVID-19 treatment among 70 preexisting clinical or under clinical trial molecules. The docking studies showed that several HIV protease inhibitors, such as lopinavir and ritonavir, demonstrated strong binding interactions with RdRp. Ledipasvir and ritonavir were identified as potential candidates for COVID-19 treatment based on simulation studies. The drug repurposing approach provides a new avenue in the search for effective treatments against COVID-19.

CURRENT PHARMACEUTICAL DESIGN (2022)

Add to Collection

Article Chemistry, Medicinal

Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity

Shenghua Gao et al.

Summary: A potent non-covalent nonpeptide Mpro inhibitor GC-14 has been discovered with high potency against Mpro and excellent antiviral activity, showing low cytotoxicity and excellent target selectivity for SARS-CoV-2 Mpro.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Letter Immunology

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections

Rune M. Pedersen et al.

Summary: In this study, it was found that after receiving 3 doses of BNT162b2 vaccine, there was improved neutralization against Omicron BA.1/BA.2 breakthrough infections.

EMERGING INFECTIOUS DISEASES (2022)

Add to Collection

Article Chemistry, Medicinal

Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease

Yuya Hirose et al.

Summary: The study reports a new class of covalent inhibitors of 3CLpro with strong antiviral activity against SARS-CoV-2 replication, showing potential in terms of biochemical efficiency and pharmacokinetic properties.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Chemistry, Medicinal

Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives

Gabriele La Monica et al.

Summary: This perspective analyzes the current research status of covalent SARS-CoV-2 MPRO inhibitors, including different categories of drugs, their mechanisms, and the roles of pharmacophoric moieties and chiral carbons. The provided analyses of noncovalent and covalent in vitro protocols are helpful for the scientific community to discover more efficient inhibitors.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Chemistry, Medicinal

Development of Ultrapure and Potent Tannic Acids as a Pan-coronal Antiviral Therapeutic

Po-Chang Shih et al.

Summary: Pentarlandir UPPTA, a pure and potent tannic acid, exhibits activity against SARS-CoV-2 and HCoV-OC43 by inhibiting viral replication through 3CLpro. It shows high antiviral efficacy against SARS-CoV-2 and distributes well in lung tissue. Toxicology studies reveal its overall safety. Therefore, Pentarlandir UPPTA is considered a safe and efficacious pancoronal antiviral drug candidate.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)

Add to Collection

Article Medicine, General & Internal

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

Summary: This study presents the final results of the Solidarity trial and meta-analyses of mortality in relevant trials. The findings suggest that remdesivir does not have a significant effect on COVID-19 patients who are already on ventilators. However, it does have a small effect against death or progression to ventilation in other hospitalized patients.

LANCET (2022)

Add to Collection

Review Virology

RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target

Yanyan Wang et al.

Summary: The global pandemic caused by the novel coronavirus has infected millions of people and urgently requires effective therapeutic measures. RdRp has been identified as a potential target for antiviral strategies, with studies showing its high conservation across different coronaviruses.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Biochemical Research Methods

Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus

Shasha Li et al.

Summary: This study identified cepharanthine (CEP) as an effective antiviral agent against a SARS-CoV-2-related virus, reversing dysregulated genes and pathways associated with cellular stress response and heat shock response. Single-cell transcriptomes analysis also showed enrichment of genes related to cellular stress responses and autophagy pathways in peripheral blood mononuclear cells from COVID-19 patients.

BRIEFINGS IN BIOINFORMATICS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap Synthesis

Liming Yan et al.

Summary: The study presents a structural snapshot of SARS-CoV-2 RTC during mRNA transcription, revealing the interaction between nsp9 and nsp12, as well as the catalytic activity of nsp12 NiRAN. The results demonstrate an intermediate state of RTC towards mRNA synthesis, providing valuable information for antiviral drug development.

CELL (2021)

Add to Collection

Letter Cell Biology

Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2

Yuanchao Xie et al.

CELL RESEARCH (2021)

Add to Collection

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial

Ivan O. Rosas et al.

Summary: In patients with severe COVID-19 pneumonia, tocilizumab plus remdesivir did not reduce the time to hospital discharge or readiness for discharge compared to placebo plus remdesivir by day 28.

INTENSIVE CARE MEDICINE (2021)

Add to Collection

Review Medicine, General & Internal

Major Update: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points

Anjum S. Kaka et al.

Summary: The study suggests that remdesivir may not significantly reduce mortality in COVID-19 patients, but it likely improves the percentage of patients who recover and reduces serious harms. It may also result in a small decrease in the proportion of patients needing ventilation.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity

Chunlong Ma et al.

Summary: This study introduces a rational design of covalent SARS-CoV-2 M-pro inhibitors with novel cysteine reactive warheads, demonstrating potent enzymatic inhibition, antiviral activity, and improved target specificity compared to existing compounds. The promising lead candidates exhibit high selectivity over host proteases and are valuable chemical probes for target validation and potential drug development against SARS-CoV-2.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)

Add to Collection

Article Plant Sciences

Antiviral Bafilomycins from a Feces-Inhabiting Streptomyces sp.

Xi Xie et al.

Summary: A new bafilomycin derivative and known bafilomycins isolated from Streptomyces sp. HTL16 showed potent antiviral activities against influenza A and SARS-CoV-2 viruses by inhibiting endosomal ATP-driven proton pumps, with IC50 values in the nanomolar range.

JOURNAL OF NATURAL PRODUCTS (2021)

Add to Collection

Article Multidisciplinary Sciences

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen et al.

Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

Kris M. White et al.

Summary: The study revealed that plitidepsin possesses potent antiviral activity against SARS-CoV-2, more effective than the approved drug remdesivir. By inhibiting the eukaryotic translation elongation factor 1A, plitidepsin can significantly reduce viral replication of SARS-CoV-2 in the lungs of mice, making it a promising candidate for COVID-19 treatment.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 M-pro inhibitors with antiviral activity in a transgenic mouse model

Jingxin Qiao et al.

Summary: The study designed and synthesized 32 new M-pro inhibitors containing bicycloproline, which showed inhibitory effects on SARS-CoV-2. Compounds MI-09 and MI-30 exhibited excellent antiviral activity in cell-based assays and significantly reduced lung viral loads and lung lesions in a transgenic mouse model of SARS-CoV-2 infection. Both also displayed good pharmacokinetic properties and safety in rats.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Britton Boras et al.

Summary: Researchers found that PF-07304814 exhibits broad-spectrum activity in inhibiting SARS-CoV and SARS-CoV-2, supported by its ADME and safety profile for clinical development. The 3CL protease, crucial in various coronaviruses, is effectively inhibited by PF-00835231 as a single agent, and shows even better results in combination with remdesivir.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants

Pengcheng Han et al.

Summary: Multiple SARS-CoV-2 variants, including Alpha, Beta, and Gamma, were studied in terms of their interactions with the human ACE2 receptor. The study identified key residues in the receptor-binding domain that affect binding affinity and demonstrated the potential of soluble ACE2 protein in preventing viral entry. The findings could contribute to the development of novel therapeutic and prophylactic agents targeting these emerging mutants.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations

Chun-Hui Zhang et al.

Summary: Starting from known drugs, the study redesigned perampanel into potent noncovalent inhibitors of SARS-CoV-2 main protease with ca. 20 nM IC50 values. Free-energy perturbation calculations and high-resolution X-ray crystal structures guided the design efforts and rapid development of effective analogues. Cell-based antiviral assays confirmed the potential of the compounds for COVID-19 treatment, highlighting the power of computational chemistry in drug discovery.

ACS CENTRAL SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

Sebastian Guenther et al.

Summary: The study identified 37 compounds that bind to the SARS-CoV-2 main protease through a high-throughput x-ray crystallographic screen of two repurposing drug libraries. Among these compounds, one peptidomimetic and six nonpeptidic compounds showed antiviral activity in cell-based viral reduction assays at nontoxic concentrations. The identification of two allosteric binding sites presents potential targets for drug development against SARS-CoV-2.

SCIENCE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment

Jiashu Xie et al.

Summary: The study examined the potential of Remdesivir and its parent nucleoside GS-441524 as oral drugs for treating COVID-19. Results showed that Remdesivir had poor stability in vitro, while GS-441524 exhibited better metabolic stability and oral bioavailability, indicating its potential as a promising oral antiviral drug for COVID-19 treatment.

ACTA PHARMACEUTICA SINICA B (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses

Hong Zhou et al.

Summary: A study in Yunnan province, China, found the existence of bat coronaviruses related to both SARS-CoV-2 and SARS-CoV, with RpYN06 virus being the closest relative of SARS-CoV-2. Ecological modeling predicted the co-existence of up to 23 Rhinolophus bat species, with the largest hot-spots extending from South Laos and Vietnam to southern China. The study highlights the remarkable diversity of bat coronaviruses at the local scale.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Coupling of N7-methyltransferase and 3′-5′ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading

Liming Yan et al.

Summary: The study presents the cryo-EM structure of the SARS-CoV-2 replication-transcription complex (RTC) Cap(0)-RTC, demonstrating the proofreading mechanism of nsp14 and the role of nsp10/nsp14 in the formation of the capping complex.

CELL (2021)

Add to Collection

Review Pharmacology & Pharmacy

Drug metabolic stability in early drug discovery to develop potential lead compounds

Siva Nageswara Rao Gajula et al.

Summary: Understanding the metabolic stability of a drug substance is crucial for determining dosing and frequency. Modifying lead compounds can improve metabolic stability and reduce dosing frequency. Predicting in vivo total clearance can be done through in vitro intrinsic clearance data and hepatic clearance models.

DRUG METABOLISM REVIEWS (2021)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Decoding molnupiravir-induced mutagenesis in SARS-CoV-2

Luis Menendez-Arias

Summary: Molnupiravir can be incorporated into viral RNA and used as template for RNA synthesis, leading to error catastrophe in SARS-CoV-2.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

Add to Collection

Article Chemistry, Medicinal

Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease

Chamandi S. Dampalla et al.

Summary: Novel inhibitors have been synthesized that effectively inhibit coronavirus protease, showing potential for treating COVID-19 and providing a means to access new chemical space and optimize pharmacological activity.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

Florian Kabinger et al.

Summary: Molnupiravir is an oral antiviral drug candidate that increases viral RNA mutations frequency and inhibits replication of SARS-CoV-2 by altering the substrate preference of RdRp. This two-step mutagenesis mechanism can explain the broad-spectrum antiviral activity of molnupiravir, making it a promising COVID-19 treatment option.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets

Nunziata Maio et al.

Summary: Research has shown that the catalytic subunit nsp12 of the SARS-CoV-2 RdRp complex ligates two iron-sulfur metal cofactors which are essential for viral replication and interaction with the viral helicase. Oxidation of these clusters by TEMPOL inhibits RdRp activity and blocks SARS-CoV-2 replication in cell culture, indicating that these iron-sulfur clusters could be targeted for therapy of COVID-19.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

Nir Drayman et al.

Summary: This study identified a drug called masitinib that can inhibit the replication of both SARS-CoV-2 and OC43 virus, and acts by competitively inhibiting 3CLpro. The drug showed strong antiviral effects in in vivo experiments on mice infected with SARS-CoV-2, and was effective against multiple variants in vitro.

SCIENCE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

SARS-CoV-2: from its discovery to genome structure, transcription, and replication

Ayslan Castro Brant et al.

Summary: SARS-CoV-2 is a highly contagious respiratory virus causing adult atypical pneumonia COVID-19 with severe acute respiratory syndrome (SARS). This virus enters susceptible cells and directly translates polyproteins to initiate viral genome replication and transcription.

CELL AND BIOSCIENCE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer

Liyan Yang et al.

Summary: The COVID-19 pandemic and lung cancer have posed serious threats to global public health, and recent studies have shown that natural products may serve as effective treatments for lung diseases, particularly in combination therapy and with the assistance of nanotechnology.

BIOMEDICINES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients

Jin-Lan Zhang et al.

Summary: FNC, a nucleoside analog, has shown activity against HIV-1 and SARS-CoV-2. Research suggests FNC's anti-viral effect is concentrated in the thymus, promoting immunity. Clinical trials have demonstrated oral FNC's ability to effectively cure COVID-19 patients.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery

Zhonglei Wang et al.

Summary: This study focuses on utilizing X-ray crystal structures and computational analysis to discover and optimize anti-SARS-CoV-2 drugs, with a focus on the interaction of newly identified small-molecule inhibitors with drug targets.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)

Add to Collection

Article Chemistry, Medicinal

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir

Zilei Xia et al.

Summary: Novel hybrid inhibitors UAWJ9-36-1 and UAWJ9-36-3, designed based on the crystal structure of SARS-CoV-2 M-Pro, showed potent enzymatic inhibition against multiple human coronaviruses. These inhibitors have promising potential as broad-spectrum antivirals against coronaviruses.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)

Add to Collection

Letter Gastroenterology & Hepatology

Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis

Guo-Fu Li et al.

GUT (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development

Miao-Miao Zhao et al.

Summary: CTSL plays a crucial role in COVID-19 patients, with its levels positively correlated with disease severity. Research showed that CTSL promotes SARS-CoV-2 virus entry into cells, and the CTSL inhibitor amantadine can inhibit this process, providing a direction for the development of new anti-COVID-19 drugs.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Letter Biochemistry & Molecular Biology

Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products

Chang-Long He et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Letter Cell Biology

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Manli Wang et al.

CELL RESEARCH (2020)

Add to Collection

Article Virology

The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses

Na Xu et al.

JOURNAL OF VIROLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

A new coronavirus associated with human respiratory disease in China

Fan Wu et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Renhong Yan et al.

SCIENCE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase

Quan Wang et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Qihui Wang et al.

CELL (2020)

Add to Collection

Article Medicine, General & Internal

Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model

Hua-Hao Fan et al.

CHINESE MEDICAL JOURNAL (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Wenhao Dai et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Yan Gao et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Linlin Zhang et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Wanchao Yin et al.

SCIENCE (2020)

Add to Collection

Article Cell Biology

Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2

Qi Peng et al.

CELL REPORTS (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Yeming Wang et al.

LANCET (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of replicating SARS-CoV-2 polymerase

Hauke S. Hillen et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Jun Lan et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

Tommy Tsan-Yuk Lam et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Zhenming Jin et al.

NATURE (2020)

Add to Collection

Article Cell Biology

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Chunlong Ma et al.

CELL RESEARCH (2020)

Add to Collection

Article Chemistry, Multidisciplinary

A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study

Zhigang Ren et al.

ADVANCED SCIENCE (2020)

Add to Collection

Article Chemistry, Medicinal

Mechanistic Insight into Antiretroviral Potency of 2′-Deoxy-2′-β-fluoro-4′-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention

Li Sun et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular Architecture of the SARS-CoV-2 Virus

Hangping Yao et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Donghyuk Shin et al.

NATURE (2020)

Add to Collection

Review Pharmacology & Pharmacy

Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor

Yanwei Li et al.

PHARMACOLOGICAL RESEARCH (2020)

Add to Collection

Article Multidisciplinary Sciences

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Xiangyang Chi et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Zhe Lv et al.

SCIENCE (2020)

Add to Collection

Article Chemistry, Medicinal

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

Robert L. Hoffman et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection

Article Chemistry, Physical

Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase

Mark Andrew White et al.

JOURNAL OF PHYSICAL CHEMISTRY LETTERS (2020)

Add to Collection

Article Multidisciplinary Sciences

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Zunlong Ke et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Architecture of a SARS-CoV-2 mini replication and transcription complex

Liming Yan et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Covid-19: What now for remdesivir?

Jeremy Hsu

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Review Biochemistry & Molecular Biology

ACE2: the molecular doorway to SARS-CoV-2

Miriam Marlene Medina-Enriquez et al.

CELL AND BIOSCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L

Michael Dominic Sacco et al.

SCIENCE ADVANCES (2020)

Add to Collection

Review Chemistry, Multidisciplinary

GS-5734: a potentially approved drug by FDA against SARS-Cov-2

Zhonglei Wang et al.

NEW JOURNAL OF CHEMISTRY (2020)

Add to Collection

Article Infectious Diseases

Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis

Laura K. McMullan et al.

LANCET INFECTIOUS DISEASES (2019)

Add to Collection

Review Plant Sciences

Cepharanthine: An update of its mode of action, pharmacological properties and medical applications

Christian Bailly

PHYTOMEDICINE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells

Dong Eon Kim et al.

BIOMOLECULES (2019)

Add to Collection

Article Multidisciplinary Sciences

Recombinant RNA-Dependent RNA Polymerase Complex of Ebola Virus

Egor P. Tchesnokov et al.

SCIENTIFIC REPORTS (2018)

Add to Collection

Article Chemistry, Medicinal

Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo(2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

Dustin Siegel et al.

JOURNAL OF MEDICINAL CHEMISTRY (2017)

Add to Collection

Article Cell Biology

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Timothy P. Sheahan et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Late Ebola virus relapse causing meningoencephalitis: a case report

Michael Jacobs et al.

LANCET (2016)

Add to Collection

Article Multidisciplinary Sciences

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Travis K. Warren et al.

NATURE (2016)

Add to Collection

Article Chemistry, Analytical

Quantification of 2′-deoxy-2′-β-fluoro-4′-azidocytidine in rat and dog plasma using liquid chromatography-quadrupole time-of-flight and liquid chromatography-triple quadrupole mass spectrometry: Application to bioavailability and pharmacokinetic studies

Youmei Peng et al.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2014)

Add to Collection

Article Chemistry, Medicinal

Synthesis of new 2′-deoxy-2′-fluoro-4′-azido nucleoside analogues as potent anti-HIV agents

Qiang Wang et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)

Add to Collection

Article Chemistry, Medicinal

The Design, Synthesis, and Antiviral Activity of 4′-Azidocytidine Analogues against Hepatitis C Virus Replication: The Discovery of 4′-Azidoarabinocytidine

David B. Smith et al.

JOURNAL OF MEDICINAL CHEMISTRY (2009)

Add to Collection

Article Chemistry, Medicinal

The Design, Synthesis, and Antiviral Activity of Monofluoro and Difluoro Analogues of 4′-Azidocytidine against Hepatitis C Virus Replication: The Discovery of 4′-Azido-2′-deoxy-2′-fluorocytidine and 4′-Azido-2′-dideoxy-2′,2′-difluorocytidine

David B. Smith et al.

JOURNAL OF MEDICINAL CHEMISTRY (2009)

Add to Collection

Article Biochemistry & Molecular Biology

2′-deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-α-hydroxyl groups

Klaus Klumpp et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2008)

Add to Collection

Article Chemistry, Medicinal

Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication:: The discovery of R1479

David B. Smith et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)

Add to Collection

Article Biochemistry & Molecular Biology

The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture

K Klumpp et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

Add to Collection

Article Biochemistry & Molecular Biology

Design of wide-spectrum inhibitors targeting coronavirus main proteases

HT Yang et al.

PLOS BIOLOGY (2005)

Add to Collection

Article Multidisciplinary Sciences

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

HT Yang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.